Basecamp Wealth Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
Other funds holding AZN
Basecamp Wealth Advisors's AZN Position: Q3 2026 in Review
Basecamp Wealth Advisors reduced its AstraZeneca (AZN) stake by 35% in Q3 2026, selling an estimated $392K and leaving 4,311 shares worth $696K. The position accounts for 0.16% of the portfolio, ranked #66.
Basecamp Wealth Advisors first reported a position in AZN in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.31M in Q1 2026. 1,429 funds tracked by Wall St. Rank hold AZN as of Q3 2026.
- Basecamp Wealth Advisors held 4,311 shares of AstraZeneca worth $696K as of Q3 2026.
- Basecamp Wealth Advisors sold 2,355 AstraZeneca shares in Q3 2026, an estimated $392K.
- AstraZeneca made up 0.16% of Basecamp Wealth Advisors's portfolio in Q3 2026, its #66 holding.
- Basecamp Wealth Advisors first reported a position in AstraZeneca in Q4 2025 and has held it in 4 quarters since.
- Basecamp Wealth Advisors's AstraZeneca position peaked at $1.31M in Q1 2026.
- 1,429 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.
Based on Basecamp Wealth Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.